Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised …
…, C Stach, B Hoepken, A Fichtner, G Coteur… - Annals of the …, 2014 - ard.bmj.com
Objectives To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in
RAPID-axSpA ( NCT01087762 ), an ongoing Phase 3 trial in patients with axial …
RAPID-axSpA ( NCT01087762 ), an ongoing Phase 3 trial in patients with axial …
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy …
…, D Borenstein, J Box, G Coteur… - Annals of the …, 2009 - ard.bmj.com
Background: Tumour necrosis factor α (TNFα) is a proinflammatory cytokine involved in the
pathogenesis of rheumatoid arthritis (RA). Treatment with TNFα inhibitors reduces disease …
pathogenesis of rheumatoid arthritis (RA). Treatment with TNFα inhibitors reduces disease …
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo‐controlled trial …
…, AB Gottlieb, IJ Terpstra, G Coteur… - British Journal of …, 2012 - academic.oup.com
Background Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent.
Objectives To evaluate the efficacy and safety of CZP in patients with plaque psoriasis. Methods …
Objectives To evaluate the efficacy and safety of CZP in patients with plaque psoriasis. Methods …
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial
…, ZH Younes, R Bloomfield, G Coteur… - Clinical …, 2011 - Elsevier
BACKGROUND & AIMS: Certolizumab pegol (CZP) is a pegylated-conjugated Fab′ against
tumor necrosis factor (TNF). Additional data are needed regarding the efficacy of induction …
tumor necrosis factor (TNF). Additional data are needed regarding the efficacy of induction …
Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn's disease
G Coteur, B Feagan, DL Keininger… - Alimentary …, 2009 - Wiley Online Library
Background Crohn’s disease (CD) is a chronic inflammatory illness characterized by episodic
abdominal pain, diarrhoea, fever, bleeding and obstruction. While the Crohn’s Disease …
abdominal pain, diarrhoea, fever, bleeding and obstruction. While the Crohn’s Disease …
[PDF][PDF] Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24‐week patient‐reported outcome results of a phase III, multicenter …
D Gladman, R Fleischmann, G Coteur… - Arthritis care & …, 2014 - Wiley Online Library
Objective To examine the effect of certolizumab pegol (CZP) on patient‐reported outcomes (PROs)
in psoriatic arthritis (PsA) patients with and without prior tumor necrosis factor (TNF) …
in psoriatic arthritis (PsA) patients with and without prior tumor necrosis factor (TNF) …
Reactive oxygen species (ROS) production by amoebocytes of Asterias rubens (Echinodermata)
G Coteur, M Warnau, M Jangoux, P Dubois - Fish & Shellfish Immunology, 2002 - Elsevier
… The suspension was then centrifuged (400 g, 10 min, 4 C) and the supernatant replaced by
CMFASW, … G. Pagano and an anonymous referee for the critical reading of the manuscript. …
CMFASW, … G. Pagano and an anonymous referee for the critical reading of the manuscript. …
Are patient-reported outcome instruments for ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis
A van Tubergen, PM Black, G Coteur - Rheumatology, 2015 - academic.oup.com
… Black, Geoffroy Coteur, Are patient-reported outcome instruments for ankylosing spondylitis
fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis, …
fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis, …
[HTML][HTML] Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ)
D Keininger, G Coteur - Health and quality of life outcomes, 2011 - Springer
Background Subcutaneous self-injection of medication has benefits for the patient and healthcare
system, but there are barriers such as dexterity problems and injection anxiety that can …
system, but there are barriers such as dexterity problems and injection anxiety that can …
[HTML][HTML] Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with …
…, P Mease, GR Burmester, E Nikaï, G Coteur… - Arthritis research & …, 2009 - Springer
Introduction The objective of this study was to assess the impact of certolizumab pegol (CZP)
treatment on health-related quality of life (HRQoL), fatigue and other patient-reported …
treatment on health-related quality of life (HRQoL), fatigue and other patient-reported …